J.P. Morgan AG (RNS)

Nachricht vom 18.08.2021 | 14:30

J.P. Morgan AG: Stabilisation Notice

DGAP-News: J.P. Morgan AG / Key word(s): Miscellaneous
18.08.2021 / 14:30
The issuer is solely responsible for the content of this announcement.

Novem Group S.A.: Notification on the implementation of stabilisation measures
The issuer of this notice is solely responsible for the content of this announcement.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
18 August 2021
Novem Group SA
Stabilisation Notice
J.P. Morgan AG (contact: Stefan Weiner, tel.: +49 69 71240) hereby gives notice that, acting as the Stabilisation Manager, it undertook stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) in relation to the offer of securities, as set out below:
Issuer: Novem Group S.A.
Guarantor (if any): N.A.
Aggregate nominal amount: 14,984,848 no-par value shares
Description: No-par value shares
ISIN LU235631474
Offer price: EUR 16.50
Other offer terms: N.A. 
Stabilisation:
Stabilising Manager(s): JP Morgan AG
Existence, maximum size of over-allotment option: 1,954,545 no-par value shares
Stabilisation market place: Prime Standard, Frankfurt Stock Exchange, Xetra
 
Stabilisations:
Date Amount Execution price Marketplace
    (EUR)  
19-Jul-21 1,050,000 16.425546 XETR
20-Jul-21 51,429 16.499693 XETR
21-Jul-21 25,479 16.499545 XETR
22-Jul-21 15,947 16.500000 XETR
23-Jul-21 31,710 16.498937 XETR
26-Jul-21 50,646 16.494418 XETR
27-Jul-21 879 16.500000 XETR
30-Jul-21 5,261 16.500000 XETR
02-Aug-21 16 16.500000 XETR
04-Aug-21 1,424 16.500000 XETR
05-Aug-21 424 16.500000 XETR
Stabilisation period: Total amount: Weighted average price:  
19 Jul 21 - 17 Aug 21 1,233,215.00 16.436329  
 
Important Notice
This announcement does not contain or constitute an offer to sell nor a solicitation to buy or subscribe for securities.
This announcement is not a prospectus. Potential investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of the information contained in the prospectus of the Company (including any supplements thereto) which has been approved by the German federal financial supervisory authority (Bundesanstalt für Finanzdienstleistungsaufsicht - BaFin) and immediately published thereafter. Copies of such prospectus are available free of charge from Novem Group SA, as well as, for viewing in electronic form, on the website of the Company.
This announcement is not an offer of securities for sale in the United States of America (the "United States"). Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company and that would contain detailed information about the Company and its management, as well as the financial statements of the Company. There will be no public offer of the securities in the United States.
In the United Kingdom, this information is directed at and/or for distribution only to (i) investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) high net worth companies falling within article 49(2)(a) to (d) of the Order (all such persons are collectively referred to herein as "relevant persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this information or any of its contents.
In member states of the European Economic Area ("EEA"), in which the Regulation (EU) 2017/1129 as amended (the "Prospectus Regulation") is in effect other than Germany (the "Relevant Member States"), this announcement, and any offer following it, is only addressed to persons who are 'qualified investors' within the meaning of Article 2(e) of the Prospectus Regulation ("Qualified Investors"). It is assumed that each person in the Relevant Member States who acquires or is offered securities as part of an offering (an "Investor") has represented and agreed that such person is a Qualified Investor; that securities purchased by such person as part of the offering are not being purchased for any person in the EEA other than a Qualified Investor or persons in Germany or another Relevant Member State with comparable legal provisions, with respect to whom the Investor may make decisions at its own discretion; and that the securities would not be purchased for offer or re-sale in the EEA, if this would lead to Novem Group SA or any of its affiliates being required to publish a prospectus under Article 3 of the Prospectus Regulation.
Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.
 


18.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021